- Home
- CMAX vs LGVN Comparison
CMAX vs LGVN Comparison
Compare CMAX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- LGVN
- Stock Information
- Founded
- CMAX 2011
- LGVN 2014
- Country
- CMAX United States
- LGVN United States
- Employees
- CMAX N/A
- LGVN N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CMAX Technology
- LGVN Health Care
- Exchange
- CMAX Nasdaq
- LGVN Nasdaq
- Market Cap
- CMAX 7.6M
- LGVN 25.9M
- IPO Year
- CMAX N/A
- LGVN 2021
- Fundamental
- Price
- CMAX $1.85
- LGVN $2.09
- Analyst Decision
- CMAX Hold
- LGVN Strong Buy
- Analyst Count
- CMAX 2
- LGVN 2
- Target Price
- CMAX $33.20
- LGVN $8.00
- AVG Volume (30 Days)
- CMAX 58.0K
- LGVN 393.6K
- Earning Date
- CMAX 11-07-2024
- LGVN 11-08-2024
- Dividend Yield
- CMAX N/A
- LGVN N/A
- EPS Growth
- CMAX N/A
- LGVN N/A
- EPS
- CMAX N/A
- LGVN N/A
- Revenue
- CMAX $784,551,000.00
- LGVN $1,229,000.00
- Revenue This Year
- CMAX $13.01
- LGVN $161.78
- Revenue Next Year
- CMAX $32.42
- LGVN $8.62
- P/E Ratio
- CMAX N/A
- LGVN N/A
- Revenue Growth
- CMAX 9.06
- LGVN 39.34
- 52 Week Low
- CMAX $1.55
- LGVN $0.77
- 52 Week High
- CMAX $74.70
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- CMAX 46.01
- LGVN 54.70
- Support Level
- CMAX $1.60
- LGVN $1.76
- Resistance Level
- CMAX $2.39
- LGVN $2.26
- Average True Range (ATR)
- CMAX 0.19
- LGVN 0.12
- MACD
- CMAX 0.07
- LGVN 0.05
- Stochastic Oscillator
- CMAX 32.50
- LGVN 66.00
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.